NO962294L - Krystallinsk, polymorf form av (S,S,S)-N-(1-[2-karboksy-3-(N2-mesyllysylamino)propylÅ-1-cyklopentylkarbonyl)-tyrosin - Google Patents

Krystallinsk, polymorf form av (S,S,S)-N-(1-[2-karboksy-3-(N2-mesyllysylamino)propylÅ-1-cyklopentylkarbonyl)-tyrosin

Info

Publication number
NO962294L
NO962294L NO962294A NO962294A NO962294L NO 962294 L NO962294 L NO 962294L NO 962294 A NO962294 A NO 962294A NO 962294 A NO962294 A NO 962294A NO 962294 L NO962294 L NO 962294L
Authority
NO
Norway
Prior art keywords
polymorphic form
crystalline
mesyllysylamino
cyclopentylcarbonyl
tyrosine
Prior art date
Application number
NO962294A
Other languages
English (en)
Other versions
NO962294D0 (no
NO306714B1 (no
Inventor
Peter James Dunn
Michael Leslie Hughes
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of NO962294D0 publication Critical patent/NO962294D0/no
Publication of NO962294L publication Critical patent/NO962294L/no
Publication of NO306714B1 publication Critical patent/NO306714B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO962294A 1993-12-04 1996-06-04 Krystallinsk, polymorf form av (S,S,S)-N-(1-[2-karboksy-3-(N2-mesyllysylamino)propyl]-1-cyklopentylkarbonyl)-tyrosin NO306714B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939324931A GB9324931D0 (en) 1993-12-04 1993-12-04 Glutaramide derivatives
PCT/EP1994/003750 WO1995015308A1 (en) 1993-12-04 1994-11-09 Crystalline, polymorphic form of (s,s,s)-n-(1-[2-carboxy-3-(n2-mesyllysylamino)propyl]-1-cyclopentylcarbonyl)tyrosine

Publications (3)

Publication Number Publication Date
NO962294D0 NO962294D0 (no) 1996-06-04
NO962294L true NO962294L (no) 1996-06-04
NO306714B1 NO306714B1 (no) 1999-12-13

Family

ID=10746163

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962294A NO306714B1 (no) 1993-12-04 1996-06-04 Krystallinsk, polymorf form av (S,S,S)-N-(1-[2-karboksy-3-(N2-mesyllysylamino)propyl]-1-cyklopentylkarbonyl)-tyrosin

Country Status (26)

Country Link
US (1) US6180665B1 (no)
EP (1) EP0731787B1 (no)
JP (1) JP2701988B2 (no)
KR (1) KR100203314B1 (no)
CN (1) CN1068586C (no)
AT (1) ATE175664T1 (no)
CA (1) CA2178085C (no)
CZ (1) CZ296428B6 (no)
DE (1) DE69416003T2 (no)
DK (1) DK0731787T3 (no)
EG (1) EG20562A (no)
ES (1) ES2128031T3 (no)
FI (1) FI120305B (no)
GB (1) GB9324931D0 (no)
GR (1) GR3029590T3 (no)
HU (1) HU225959B1 (no)
IL (1) IL111791A (no)
MY (1) MY115430A (no)
NO (1) NO306714B1 (no)
NZ (1) NZ276087A (no)
PE (1) PE9296A1 (no)
PL (1) PL178559B1 (no)
RU (1) RU2131869C1 (no)
TW (2) TW534901B (no)
WO (1) WO1995015308A1 (no)
ZA (1) ZA949595B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018217A1 (en) 2000-08-29 2002-03-07 Riverside Forest Products Limited Collapsible bin
FR2824477B1 (fr) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
US6975515B2 (en) 2001-08-15 2005-12-13 Agilent Technologies, Inc. Electrical module
DE202004021379U1 (de) * 2003-02-12 2008-02-21 Ciba Specialty Chemicals Holding Inc. Kristalline Formen von Pitivastatin Calcium
WO2005123702A1 (en) * 2004-06-15 2005-12-29 Pfizer Limited Neutral endopeptidase inhibitor polymorph
CN109350736A (zh) * 2018-09-20 2019-02-19 南通大学 防治运动病、梅尼埃病的药物及心房钠尿肽的医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820844D0 (en) * 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use

Also Published As

Publication number Publication date
TW434210B (en) 2001-05-16
HU225959B1 (en) 2008-01-28
EP0731787B1 (en) 1999-01-13
CZ296428B6 (cs) 2006-03-15
CN1142816A (zh) 1997-02-12
HUT74683A (en) 1997-01-28
NO962294D0 (no) 1996-06-04
IL111791A0 (en) 1995-01-24
PL178559B1 (pl) 2000-05-31
ES2128031T3 (es) 1999-05-01
US6180665B1 (en) 2001-01-30
GB9324931D0 (en) 1994-01-26
MY115430A (en) 2003-06-30
EP0731787A1 (en) 1996-09-18
PL314794A1 (en) 1996-09-30
CZ160496A3 (en) 1996-11-13
ATE175664T1 (de) 1999-01-15
RU2131869C1 (ru) 1999-06-20
CA2178085C (en) 2002-09-03
KR960706470A (ko) 1996-12-09
HU9601506D0 (en) 1996-07-29
PE9296A1 (es) 1996-04-04
EG20562A (en) 1999-08-30
FI120305B (fi) 2009-09-15
DE69416003T2 (de) 1999-05-27
DK0731787T3 (da) 1999-08-30
GR3029590T3 (en) 1999-06-30
JP2701988B2 (ja) 1998-01-21
AU684114B2 (en) 1997-12-04
TW534901B (en) 2003-06-01
CA2178085A1 (en) 1995-06-08
CN1068586C (zh) 2001-07-18
ZA949595B (en) 1996-06-03
FI962322A (fi) 1996-06-03
KR100203314B1 (ko) 1999-06-15
NO306714B1 (no) 1999-12-13
NZ276087A (en) 1997-11-24
FI962322A0 (fi) 1996-06-03
DE69416003D1 (en) 1999-02-25
IL111791A (en) 2002-09-12
JPH09500654A (ja) 1997-01-21
WO1995015308A1 (en) 1995-06-08
AU8142494A (en) 1995-06-19

Similar Documents

Publication Publication Date Title
YU34896A (sh) Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije
FI932229A (fi) Azabicykliska bryggderivat
BG103485A (en) Ketobanzamides as calpain inhibitors
DE69729583D1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
DK0696281T3 (da) Hidtil ukendte 5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazolderivater
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
NZ279397A (en) Mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives and pharmaceutucal compositions
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
MX9306425A (es) Compuestos benzoheterociclicos, procedimiento parasu preparacion y composiciones antagonistas de la vasopresina y la oxitocina, que contienen dichos compuestos.
NO941958L (no) Fremstilling av substituerte piperidiner
NZ331875A (en) Asymmetric synthesis of R-alpha-propyl-piperonyl amine and its analogs
NO306714B1 (no) Krystallinsk, polymorf form av (S,S,S)-N-(1-[2-karboksy-3-(N2-mesyllysylamino)propyl]-1-cyklopentylkarbonyl)-tyrosin
FI963168A0 (fi) Enkefalinaasin inhibiittoreina käyttökelpoisia uusia indaani-2-merkaptoasetyyliamiddisulfidijohdannaisia
IL138638A0 (en) Processes for preparing intermediates
DE69827614D1 (de) Chinoxalindionen
CA2171972A1 (en) Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees